Apical sodium-dependent bile acid transporter (ASBT, known as ileal bile acid transporter (IBAT) and SLC10A2) inhibition for 16 weeks improved multiple features of NASH in a high unsaturated fat diet (HFD) mouse model [30]. The gene discussed is SLC10A2; the disease is metabolic dysfunction-associated steatohepatitis.